SE travoprost implant outperforms topical PGA monotherapy in IOP control
The slow-eluting (SE) travoprost intracameral implant provides significantly greater and clinically meaningful intraocular pressure (IOP) reduction compared to topical prostaglandin analog monotherapy, according to a study.
The study, which included 133 patients, required a washout of pre-study topical PGA therapy before randomization to the SE travoprost intracameral implant.
The SE travoprost implant achieved a statistically and clinically significant 7.07 mmHg reduction in IOP, outperforming the 5.76 mmHg reduction with pre-study topical PGA monotherapy by 1.31 mmHg (95% CI: -2.01 to -0.60; P = 0.0003).
The findings suggest the SE travoprost intracameral implant provides superior IOP control, likely due to its continuous drug release and improved adherence compared to traditional topical therapy.
Reference
Bacharach J, Doan LV, Stephens KG, et al. Travoprost Intracameral Implant Demonstrates Superior IOP Lowering Versus Topical Prostaglandin Analog Monotherapy in Patients with Open-Angle Glaucoma or Ocular Hypertension. Ophthalmol Ther. 2024;13(9):2357-2367. doi: 10.1007/s40123-024-00992-1. Epub 2024 Jul 10. PMID: 38985408; PMCID: PMC11341799.
